Expertise in
18
conditions

Dr. Oliver Dorigo

Oncology
Stanford Hospital And Clinics
965 High St, 
Palo Alto, CA 
Offers Telehealth
Expertise in
18
conditions
Stanford Hospital And Clinics
965 High St, 
Palo Alto, CA 

Overview

Oliver Dorigo is an Oncologist practicing medicine in Palo Alto, California.

Dr. Dorigo is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Vulvectomy, and Bladder Reconstruction.

He is actively involved in clinical research, co-authoring 77 peer reviewed articles and participating in 5 clinical trials.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in CA

Hospital Affiliations

Stanford Health Care Tri-Valley
Stanford Health Care

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Stanford Hospital and Clinics
965 High St, Palo Alto, CA 94301
Other Locations
Stanford University
875 Blake Wilbur Dr, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: August 04, 2026
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Bintrafusp Alfa
Study Phase: Phase 2
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Enrollment Status: Completed
Publish Date: June 27, 2019
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN
Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN
Enrollment Status: Terminated
Publish Date: December 19, 2018
Intervention Type: Diagnostic test
Study Phase: Not Applicable
View 4 Less Clinical Trials

77 Total Publications

Targeting CD24 activates macrophages to reduce tumor burden in preclinical models of solid tumors.
Targeting CD24 activates macrophages to reduce tumor burden in preclinical models of solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 02, 2026
Similar Doctors
Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Stanford University

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (1.1 miles away)
650-498-6000
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ranjana Advani is an Oncologist practicing medicine in Palo Alto, California. She has been practicing medicine for over 44 years. Dr. Advani is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and Tissue Biopsy.

Expertise in
34
conditions
Expertise in
34
conditions
Referral may be required

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kristen Ganjoo is an Oncologist practicing medicine in Palo Alto, California. Dr. Ganjoo is highly rated in 34 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, Gastrointestinal Stromal Tumor, and Pancreaticoduodenectomy.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joel Neal is an Oncologist practicing medicine in Palo Alto, California. Dr. Neal is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Thymic Epithelial Tumor, and Tissue Biopsy.

Frequently Asked Questions about Dr. Oliver Dorigo

How do I make an appointment with Dr. Oliver Dorigo?

You can book an appointment with Dr. Oliver Dorigo by calling their office at 650-723-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Oliver Dorigo a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Oliver Dorigo is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Oliver Dorigo specialize in?

While Dr. Oliver Dorigo is a Oncology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Malignant Mixed Mullerian Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Oliver Dorigo participate in research or clinical trials?

Yes. Dr. Oliver Dorigo has published 77 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Oliver Dorigo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Oliver Dorigo accept my insurance?

Dr. Oliver Dorigo accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 650-723-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dorigo's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 9 Advanced Conditions
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile